Perspective Therapeutics, Inc. (CATX)

1,7250 -0,0750 (-4,17%) Ab 03:36PM EDT. Markt geöffnet.

Perspective Therapeutics, Inc.

2401 Elliott Avenue
Suite 320
Seattle, WA 98121
United States
206-676-0900
https://www.perspectivetherapeutics.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 116

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Johan M. Spoor	CEO & Director	855,78k	N/A	1972
Mr. Jonathan R. Hunt	CFO & Co-Principal Financial Officer	944,35k	N/A	1967
Dr. Markus Puhlmann M.B.A., M.D.	Chief Medical Officer	633,14k	N/A	1966
Mr. Shane Cobb	Executive Vice President of Operations	N/A	N/A	N/A
Mr. Mark J. Austin CPA	VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary	N/A	N/A	1987
Dr. Michael K. Schultz Ph.D.	Chief Science Officer	N/A	N/A	N/A
Mr. Andrew Bright	Executive Vice President of Brachytherapy	N/A	N/A	N/A
Mr. Amos Hedt BA, PGradDip	Chief Business Strategy Officer	N/A	N/A	N/A
Dr. Frances L. Johnson M.D.	Chief Innovation Officer	N/A	N/A	N/A
Mr. David Hauser Ph.D.	Senior Vice President of Clinical Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Corporate Governance

Perspective Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.